Weill Cornell Medicine Neurosurgery Accepted into Apple Investigator Support Program to Advance Nighttime Seizure Detection

Weill Cornell Medicine's Department of Neurological Surgery has been accepted into the Apple Investigator Support Program. This program will launch a new clinical study exploring whether the Apple Watch can detect seizures during the night and alert caregivers in real time.

Led by Dr. Mohammed Fouda, under the supervision of Dr. Caitlin Hoffman, Associate Professor of Neurological Surgery and Director of Epilepsy Surgery Program at New Yor-Presbyterian Hospital, Weill Cornell Medicine  and in collaboration with Emma Hartman, MS2 at Weill Cornell Medicine, Daniel Lowenstein, M.D, Assistant Professor of Pediatric Neurology, New Yor-Presbyterian Hospital, Weill Cornell Medicine, and Padmaja Kandula, Chief, Epilepsy and Clinical Neurophysiology, New Yor-Presbyterian Hospital, Weill Cornell Medicine; the study will focus on two types of convulsive seizures in both adult and pediatric patients: generalized tonic-clonic (GTC) seizures and focal-to-bilateral tonic-clonic (FBTC) seizures. Both are characterized by muscle stiffening followed by rhythmic jerking movements. While GTC seizures involve both sides of the brain from the outset, FBTC seizures originate in a specific region of the brain before spreading to involve both sides.

Why nighttime seizures matter

Seizures occurring during sleep can easily go unnoticed, particularly when patients sleep alone or caregivers are in another room. By the time a seizure is recognized, it may have already ended, potentially delaying critical assistance. The moments during and immediately after a tonic-clonic seizure are particularly important, as timely intervention may help prevent serious complications.

Tonic-clonic seizures are among the strongest risk factors for Sudden Unexpected Death in Epilepsy (SUDEP), a rare but devastating complication of epilepsy. The ability to detect these seizures in real time and promptly alert caregivers could provide a critical opportunity for earlier intervention. Although further research is needed to determine whether such interventions can reduce SUDEP risk, improving nighttime seizure detection represents a promising step toward enhancing patient safety and providing greater peace of mind for patients and their families.

How the study works

The Apple Watch is equipped with a three-axis accelerometer, a sensor that measures movement-related acceleration in three directions. Through a three-phase clinical study involving pediatric and adult patients, the research team will develop and validate algorithms designed to recognize the characteristic movement patterns associated with generalized tonic-clonic (GTC) and focal-to-bilateral tonic-clonic (FBTC) seizures. The study will also evaluate whether these seizures can be detected rapidly and reliably, triggering real-time alerts to caregivers that could facilitate timely assistance and improve patient safety.

The study will be conducted in three sequential phases, involving both pediatric and adult patients with epilepsy:

Phase I – Algorithm Development and Training: Apple Watch sensor data will be collected from patients undergoing continuous video-EEG monitoring in the Epilepsy Monitoring Unit (EMU). These data will be used to develop age-specific algorithms capable of identifying nocturnal generalized tonic-clonic and focal-to-bilateral tonic-clonic seizures based primarily on wrist movements, with additional physiological signals evaluated when feasible.

Phase II – Prospective Clinical Validation: The developed algorithms will undergo independent validation in a new cohort of pediatric and adult patients, using synchronized video-EEG as the gold standard. This phase will assess seizure detection accuracy, false-alarm rates, detection speed, and the reliability of real-time alerts to designated caregivers or responders.

Phase III – Real-World Home Evaluation: Following successful clinical validation, the system will be evaluated during 30 nights of home monitoring in 100 patients (50 pediatric and 50 adult). This phase will assess the reliability of seizure alerts, caregiver response, device performance, patient adherence, and overall usability in everyday settings.

Why this research matters for patients and families

For patients with epilepsy and their families, nighttime seizures represent a significant source of fear, uncertainty, and emotional burden. Convulsive seizures occurring during sleep often go unnoticed, potentially delaying critical assistance and increasing the risk of serious complications, including sudden unexpected death in epilepsy (SUDEP). Many families live with the constant worry of missing a seizure, often disrupting their own sleep to monitor their loved ones.

This study has the potential to transform how patients and families manage these risks. By developing a reliable, Apple Watch–based system that can detect nocturnal seizures and immediately alert caregivers, we hope to enable faster intervention, provide greater reassurance, and reduce the burden of constant nighttime supervision. Importantly, leveraging a widely available consumer device could make seizure-monitoring technology more accessible and practical for everyday use.

Because the Apple Watch is a widely available consumer device, the research could help pave the way for seizure detection that is accessible, wearable and easy to use in everyday life — not just in the hospital. By bringing together wearable technology, clinical research and real-time caregiver response, the team hopes to not only to improve seizure detection and patient safety but also to empower patients to live more independently while giving their families greater peace of mind and improving quality of life for both patients and caregivers.

Learn more about epilepsy research and care at Weill Cornell Medicine.

Category:

Neurological Surgery 525 E. 68th St., Starr 651, Box 99 New York, NY 10065